**P2.094** THE CONTRIBUTION OF MACROLIDE RESISTANCE MUTATIONS TO FAILURE OF AZITHROMYCIN TREATMENT IN MYCOPLASMA GENITALIA INFECTION


1*M Bissessor, 1C K Fairley, 1M Y Chen, 1S N Tabrizi, 1U Hocking, 1C S Bradshaw, 1Melbourne Sexual Health Centre, Melbourne, Australia; 2Melbourne School of Population Health, University of Melbourne, Melbourne, Australia; 3Department of Microbiology Royal Women’s Hospital, Melbourne, Australia; 4Centre for Women’s Health, Gender and Society, University of Melbourne, Melbourne, Australia

**Background** Current recommended treatment for Mycoplasma genitalium (Mg) is azithromycin. Macrolide resistance mutations (MRM), predominantly on the 23S rRNA gene of Mg, have been found to be associated with failure of azithromycin. We aimed to determine the efficacy of 1g-azithromycin in a prospective cohort of Mg-infected STI clinic attendees, and to determine the contribution of MRM to treatment failure.

**Method** We commenced an observational study in July 2012 in which symptomatic patients diagnosed with Mg by PCR at Melbourne Sexual Health Centre are retested for Mg 14 and 28 days following treatment with 1g-azithromycin. Testing for MRM using high-resolution melt analysis (HRM) is conducted on day 0 and on positive samples at days 14 and 28. Participants are managed on the basis of clinical symptoms and not detection of MRM. Study will complete, May 2013.

**Results** 105 participants have been recruited; 89 have completed all study requirements. 48/89 (54%; 95% CIs 44–64%) participants were Mg PCR negative at day 28. 41/89 (46%; 95% CIs 36–56%) did not respond to 1g azithromycin: 11/41 (27%) had a persistently positive Mg PCR on day 28 without reported risk of re-exposure (presumptive failures) and 30 of 41 (73%) had persistent symptoms of Mg prior to day 28 and required interim treatment with moxifloxacin (probable failures). Of the 41 failures, 40 (98%) had MRM detected: 30 (75%) at baseline and 10 (25%) at day 14 only. Of the 48 azithromycin-responders 4(8%) had MRM detected at baseline.

**Conclusion** The azithromycin cure rate for Mg in this clinic cohort was only 54%. MRM were detected in virtually all cases of azithromycin-failure, and were uncommon in azithromycin-responders. The majority of MRM were detected prior to treatment. These findings have implications for the use of macrolides as current recommended treatment for M. genitalium, and highlight the need for evaluation of alternative treatment approaches.

**P2.095** ORIGINS OF REPEAT INFECTIONS WITH MYCOPLASMA GENITALIA (MG) AMONG HETEROSEXUAL MEN IN TWO SOUTHERN U.S. CITIES


1P Kissinger, 1S White, 1N Schmidt, 1S N Taylor, 1H Meno, 1R Lillis, 1S A Same, 1K Delafayette, 1D H Martin, 2Tulane University SPHTM, New Orleans, LA, United States; 3Louisiana State University Health Sciences Center, New Orleans, LA, United States; 4University of Mississippi – Department of Medicine, Jackson, MS, United States

**Background** The purpose of this study was to examine the origins of repeat infections with Mg among men. High repeat infection rates have been consistently reported and treatment failure secondary to macrolide resistance is thought to be the primary cause. This study adds to the growing literature by describing the possible origins of repeat Mg infections in among men, primarily African American, attending two public STD clinics in southern cities in the U.S.

**Methods** Men diagnosed with NGU at an STD clinic in New Orleans, Louisiana, and Jackson, Mississippi, were tested for Mg using the GenProbe research-use-only assay Mg+ men underwent a 4–10 week test of cure visit (TOC) following treatment with 1 g azithromycin. Detailed sexual behaviour data were collected at baseline and follow-up via ACASI and genotyping was performed.

**Results** Of 205 men with Mg, 135 returned for TOC visit and of those, 34.3% were positive. Of the 46 who were positive at TOC, 19.6% reported sexual re-exposure to a baseline partner, 6.5% reported sexual exposure to a new partner, 6.5% reported sexual exposure to both, and 67.4% denied sexual re-exposure. Men who re-tested positive for Mg at TOC (n = 46) were no more likely that those who tested negative (n = 88) to have had sexual exposure to a baseline partner (31.8% vs. 26.1%, P = 0.55) or exposure to a new partner (21.4% vs. 11.3%, P = 0.22). Genotyping on baseline/TOC positive pairs is being performed and will be used in conjunction with behavioural data to more precisely estimate the treatment failure rate.

**Conclusion** The TOC repeat infection rate among men with Mg is high. Our data are consistent with the published literature corroborating that repeat infections in men treated with azithromycin is usually due to treatment failure rather than re-infection. Research is needed to optimise treatment of Mg infections in men.

**P2.096** EVALUATION OF GONOCOCCAL RESISTANCE IN AUSTRIA


1A Stary, 1M Haller, 1C Heller-Vitouch, 1N Hartl, 2E Vinzelj-Horvath, 2A Geusau, 2K Rappersberger, 3P Komericki, 4J Auböck, 5R Hoepfl. 1Outpatient’s Centre for Diagnosis of Infectious Venereodermatological Diseases, Vienna, Austria; 2Outpatient’s Clinic for Sexual Transmitted Diseases, Vienna, Austria; 3Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases (DAIAD), Medical University of Vienna, Vienna, Austria; 4Department of Dermatology and Venereology, Community Hospital Krankenanstalt Rudolfstiftung, Vienna, Austria; 5Department of Dermatology and Venereology, Medical University of Graz, Graz, Austria; 6Department of Dermatology and Venereology, General Hospital, Linz, Austria; 7Department of Dermatology and Venereology, Medical University of Innsbruck, Innsbruck, Austria

**Background** The Austrian Society for Sexually Transmitted Diseases started a surveillance project in 2010 to evaluate the gonococcal resistance in Austria.

**Methods** In 2010 and 2011 a national network of 39 centres was established to collect 1569 gonococcal isolates and the anamnestic data of the patients. Gonococcal culture plates were sent from the participating laboratories to the Outpatient’s Centre in Vienna, where gonococcal resistance testing was performed by disc diffusion test, agardilution breakpoint technique, agardilution, and Etest. The following antibodies were tested: cefixime, ceftriaxone, penicillin, ciprofloxacin, azithromycin, tetracycline, spectinomycin, and gentamicin. Results were interpreted according to CLSI and EUCAST guidelines.

**Results** In Vienna, 1456 isolates were collected, whereas 111 strains were sent from the federal states. Of all collected isolates 57% were genital, 5% pharyngeal, and 7% rectal isolates, respectively. Gonococci were collected more often from men (56%) than from women, 10% of men reported homosexual contacts. A concurrent infection with Chlamydia trachomatis was observed in 15% of all patients.

While 2010 all isolates displayed susceptibility to third generation cephalosporines, in 2011 7 gonococcal strains were resistant to cefixime (MIC > 0.125 µg/ml) but still susceptible to ceftriaxone (MIC ≤ 0.125 µg/ml). Furthermore, an increase of MIC values for cefixime as well as for ceftriaxone was observed in 2011. Resistance to azithromycin increased from 1% in 2010 to 1.5% in 2011. Resistance to quinolones was detected in 58% in 2010 rising to more than 60% in 2011, respectively.

**Conclusion** Third generation cephalosporines still represent the most appropriate drug for gonococcal therapy. As Azithromycin resistance is low in Austria it is suitable for alternative therapy especially in case of coinfection with C. trachomatis. Due to the increasing MIC values for cephalosporines and the rising rates for